PGR2019-00002 Patent 9,855,302 B2

# Appendix A

# **CURRICULUM VITAE**

#### SRIDHAR MANI, M.D.

<u>Work</u>

Albert Einstein Cancer Center 1300 Morris Park Ave Chanin 302D-1 Bronx, NY 10461 Tel: 718-430-2871

Email: sridhar.mani@einstein.yu.edu

Date of Birth: January 22, 1964

<u>Present Rank</u> :	Professor, Departments of Medicine, Molecular Pharmacology and Genetics, Div. of Oncology, Albert Einstein School of Medicine (AECOM), Bronx, NY
Education:	
1983-1988	Sophie Davis School of Biomedical Education at the City College of New York <i>Degree</i> : Bachelor of Science (BS), <u>Summa Cum Laude</u>
	Major: Biomedical Science/Anthropology
1988-1990	Mount Sinai School of Medicine, New York
	Degree: Doctor of Medicine (MD), Alpha Omega Alpha
Post-graduate Training:	
1990-1992	Resident, Department of Internal Medicine, Yale New Haven Hospital, Yale University School of Medicine, New Haven, CT (Clinical Investigator Pathway in Internal Medicine)
1992-1995	Postdoctoral Fellow, Departments of Oncology and Hematology, Yale New Haven
	Hospital, Yale University School of Medicine, New Haven, CT
<b>Professional Positions:</b>	
1995-1998	Instructor, Department of Medicine, Section of Hematology/Oncology, University of
	Chicago, Chicago, IL
1997-1998	Program Director, GI Oncology, Section of Hematology/Oncology, University of Chicago,
	Chicago, IL
1999	Assistant Professor, Medicine/Oncology, Montefiore Medical Center (MMC), Bronx NY
1999- Present	Member, Albert Einstein Cancer Center, Bronx, NY
2000	Director, Phase I Program, AECCC/ Albert Einstein College of Medicine
1000	(AECOM/MMC), Bronx, NY (now emeritus)
1999	Assistant Professor, Medicine, AECOM, Bronx, NY
2003	Associate Professor, Dept. of Medicine, Div. of Oncology, AECOM
2006	Associate Professor, Dept. of Molecular Genetics, AECOM
2011	Professor, Medicine & Genetics, AECOM
2018	Professor, Molecular Pharmacology, AECOM
<b>Board Certification/Elig</b>	ibility:
1993	ABIM (Internal Medicine) (#150280); Re-certified 2003, 2012
1997	ABIM (Oncology) (#150280); Re-certified 2006, 2017

DOCKET

#### ABIM (Hematology)(#150280); Board Eligible 2013

#### **Professional Society Memberships (past and present):**

American College of Physicians (ACP) American Federation for Clinical Research (AFCR) American Association for Cancer Research (AACR) American Society of Clinical Oncology (ASCO) European Society for Medical Oncology (ESMO) Eastern Oncology Cooperative Group (ECOG) American College of Clinical Pharmacology (ACCP) American Association of Pharmaceutical Scientists (AAPS) American Society for Clinical Pharmacology and Therapeutics (ASCPT) American Society of Gene Therapy (ASGT) New York Academy of Science (NYAS) Royal Society of Medicine, UK (RSM) American Society for Biochemistry and Molecular Biology (ASBMB) American Association of Immunologists (AAI)

#### **Awards and Honors:**

1989	Alpha Omega Alpha Medical Honor Society
1992	American Medical Association/Burroughs Wellcome Leadership Award
2002	Damon Runyon – Lilly Clinical Investigator Award, New York, NY
2003	Fellow, American College of Physicians, USA
2011	Scientific Award, Society of Asian American Scientists in Cancer Research (AASCR)

#### **Awarded and Pending Patents:**

PCT/US2002/030276	Bregman DB, <u>Mani S</u> , Agrawal A, Lu Y. Sensitization of Cells to Cytotoxic Agents Using
	Oligonucleotides Directed to Nucleotide Excision Repair or Transcription Coupled Repair
	Genes. (USPTO# 20030232767)
PCT/US2002/030276	Khandimala E, Zagardo BS, Sai S, Mani S, Agrawal S. Sensitization of Cells to Cytotoxic
	Agents Using Oligonucleotides Directed to Survivin. (USPTO# 20030125287)
96700/1320 D-665	Mani S, Das B. Ketoconazole-Derivative Antagonists of Human Pregnane X Receptor and
	Uses Thereof (USPTO# 20110105522)
96700/1423 D-666	Mani S. Das B. Hypoxia targeted compounds for cancer diagnosis and therapy. (USPTO #
	20110251189)
WO/2011/072127	Mani S, Wallace B, Redinbo MR. Compounds Inhibiting microbial beta-glucuronidases.
	Patent filed with UNC & AECOM (USTPO# 2010059690).
PCT/US2013/072709	Mani S, Mukherjee S. Gut barrier dysfunction treatment and prevention. (USTPO#
	20180185422)
Filed	Mani S, Kelly L, Li H. Endogenous microbial hyperswarmers protect against intestinal
	inflammation.
Filed	Mani S, Azole PXR antagonist for Treatment of Nonalcoholic Fatty Liver Disease
	(NAFLD)
PCT/US2018/14129	Mani S et al. PXR agonists and uses thereof for gut barrier dysfunction, treatment and
	prevention

#### **Other Professional Activities:**

DOCKET

1998-1999	Member, Cancer and Leukemia Group B (CALGB)
	Pharmacology and Experimental Therapeutics (PET) Committee
1998-1999	PET Liaison to GI Committee, CALGB
1998-1999	Member, GI Solid Tumor Correlative Science Committee, CALGB
2002	Member, Eastern Cooperative Oncology Group (ECOG)
2005	Executive Committee, ECOG Experimental Therapeutics Committee
2000-2014	Member, Institutional Biosafety Committee (IBC) of AECOM, Bronx, NY
2000-2013	Member, Committee on Patents of AECOM, Bronx, NY
2000-Present	Member, NCI Organ Dysfunction Drug Development Consortium

Clinical
(

#### **Principle Investigator, National Group Trials:**

1998-1999Interracial Study of CPT-11 (Irinotecan) Pharmacokinetics in 5-Fluorouracil Refractory<br/>Colon Cancer: A Population Pharmacokinetic/Pharmacodynamic Study: MMTC# 6475<br/>9825398253CALGB# 9864

#### **Editorial Board Membership:**

DOCKET

2004-	Current Cancer Drug Targets
2004-	Current Medicinal Chemistry - Anti-Cancer Agents
2007-	Genes & Cancer
2009-	Clinical Cancer Research
2009-	Molecular Cancer Therapeutics
2009-2013	Cancer Research
2009-	Molecular Pharmacology (Associate Editor, 2015 -)
2014-	Journal of Visual Experiments (JoVE)
2015-	Journal of Biological Chemistry (JBC)
2015-	Nuclear Receptors Research (Associate Editor)

#### NIH Grants Review and Study Section Membership:

10/19/00 - 10/20/00	CA00-001/Molecular Biology NCI Special Emphasis Panel ZCA1 SRRB-D (J2)
	Interdisciplinary Teams for Molecular Target Assessment, Bethesda MD
2007	Adhoc Member, ZRG1 SSMI-Q 10: Biomedical Devices and Bioengineering Study Section
2009	Adhoc Member, National Cancer Institute, DT Scientific Review Group
2009	NIH Challenge Grants Reviewer
2009	Adhoc member, Oncology 2 - Translational Clinical Integrated Review Group
2010	Adhoc member, ZRG1 OTC-L(10) Cancer Drug Development and Therapeutics (CDDT) SBIR/STTR, NCI
2008-2010	Grant Reviewer, James and Esther King Biomedical Research Program, Florida
	Department of Health, FL
08/17/10-08/18/10	Reviewer, 2010/10 ZRG1 EMB (02) M Member Conflict: Endocrinology and Obesity
10/10/10-10/11/10	Chair, Cancer Drug Development and Therapeutics (CDDT) SBIR/STTR review panel [2011/01 ZRG1 OTC-J (10)]
3/2/11 - 3/3/11	Permanent Member, Cancer Diagnostics and Treatments SBIR/STTR panel (ZRG1-OTC-H13)
09/01/11	Permanent Member, National Cancer Institute, Developmental Therapeutics (DT) Scientific Review Group
06/23/11 - 06/30/11	Co-chair, ZRG1 OTC-H (13) B Cancer Diagnostics and Treatments (CDT) SBIR/STTR
07/0711 - 07/09/12	Adhoc Member, ZRG1 OTC-H (14) B Small Business: Cancer Diagnostics and Treatments (CDT)
07/12/13 -07/13/13	Adhoc Member, NCI P01 Special Emphasis Panel II
2014	Adhoc, Special Emphasis Panel/Scientific Review Group 2015/01 ZCA1 RPRB-O (J1) P meeting
2015	Adhoc, Drug Discovery and Molecular Pharmacology Study Section Adhoc, MIRA Grant Panel, NIGMS
2016	
	ZRG1-BDCN-W-03, ZCA1-RPRB-J-01, ASG, NIH
2016, 2017	CDMRP Reviewer
2017	R13 Review Panel, NCATS
2017	Adhoc, ASG Review Panel, NIH
2018	Adhoc, ZTR1 CG-5 (01) NCATS (NIH), Bethesda, MD
2019	BCRP, DOD Reviewer
2019	XNDA CSR, Reviewer

# 2019 Permanent Member, Xenobiotic and Nutrient Disposition and Action Study Section (XNDA), DKUS

#### International (Other) Study Section(s)

2008-	Grant Reviewer, Georgia National Science Foundation, Tbilisi, Georgia
06/30/13 -	Reviewer, Foundation for Polish Science, Warsaw, Poland
2016	Review, Italian Ministry of Health, Italy
2017	DBT, India
2018	Reviewer, Oncopole EMC <sup>2</sup> (Multi-institutional teams against cancer), Fonds de Recherche
	du Québec –Santé (FRQS), Quebec
2018	Reviewer, Czech Science Foundation, CZ
2019	Florida Department of Health

#### <u>AECOM PhD Thesis and Qualifying Committees (see *Teaching Portfolio*): Upon Request Undergraduate, Graduate and Postdoctoral Fellows/Trainees (see *Teaching Portfolio*): Upon Request AECOM Teaching (see *Teaching Portfolio*): Upon Request</u>

#### National Meeting (Podium/Poster Discussion) Presentations:

2005, 2008	Annual Meeting - American Society of Clinical Oncology
	Annual Meeting - American Association of Cancer Research
2009	NYAS: Co-Chair, Schwachman-Diamond Syndrome International Conference

#### Invited Lectures:

Invited Lectures:	
2001	Johns Hopkins Hospital, Baltimore MD/Drug Development
2002	Georgetown University Medical Center, Washington DC
2003	Dana Farber Cancer Center, Harvard University, Boston, MA
2004	Georgetown University Medical Center, Washington DC
2005	Thomas Jefferson University, Philadelphia, PA
2009	Mount Sinai School of Medicine, New York, NY
2009	University of Connecticut Health Science Center, Hartford, CT
2010	Shanghai University of Traditional Chinese Medicine, Shanghai, China
2010	City of Hope Medical Center, Duarte, CA
2010	Drexel University College of Medicine, Philadelphia, PA
2011	Medical University of South Carolina, Charleston, South Carolina
2011	OMICs Meeting, Las Vegas, NV
2012	Penn State "Symposium on Molecular Biology" (June 2012)
2012	St. Judes Children's Medical Center, Memphis, TN
2013	University of Kansas Medical Center, Kansas City, KS
	University of Connecticut Medical Center, Hartford, CT
2014	Fox Chase Chemical Diversity Center, Philadelphia, PA
2015	Experimental Biology, Boston, MA
	Palacky University, Olomouc, Czech Republic
2016	Microbiome Update 2016, BioPharma Research Council, Kean University, NJ
	University of Houston, Houston, TX
2017	Taipei Medical University, Taipei, Taiwan
2018	Brown University, Providence, RI
2018	Personalized Medicine, Gordon Research Conference, Hong Kong
2019	University of Oklahoma
2019	University of California, Davis CA
2019	Fondazione IRCCS Istituto Nazionale dei Tumori, Milan
2019	University of Perugia, Italy

**Other AECOM Committees:** 

DOCKET

Δ

LARM Find authenticated court documents without watermarks at <u>docketalarm.com</u>.

# DOCKET A L A R M



# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## **Real-Time Litigation Alerts**



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

### **Advanced Docket Research**



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## **Analytics At Your Fingertips**



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

### API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

#### LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

#### FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

#### E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.